Patent ID: 11939594
Assignee: SEATTLE CHILDREN'S HOSPITAL
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 9:
10. The method of claim 1, wherein the target locus is selected from the group consisting of joining chain of multimeric IgA and IgM (JCHAIN), immunoglobulin kappa light chain constant region (IGKC), immunoglobulin M heavy chain constant region (IGMC), paraoxonase 3 (PON3), proteoglycan 2 (PRG2), FK506-binding protein 11 (FKBP11), syndecan 1 (SDC1), secretory leukocyte protease inhibitor (SLPI), derlin-3 (DERL3), endoplasmic reticulum degradation-enhancing alpha-mannosidase-like protein 1 (EDEM1), lymphocyte antigen 6 complex, locus C2 (LY6C2), cysteine-rich protein with epidermal growth factor-like domains 2 (CRELD2), RNA exonuclease 2 (REXO2), protein disulfide isomerase family A member 4 (PDIA4), pattern recognition domain-containing protein 1 (PRDM1), caspase recruitment domain-containing protein 11 (CARD11), chemokine CC motif receptor 5 (CCR5), and stromal cell-derived factor 2-like 1 (SDF2L1).